GleanMark

GLOBIN SWITCHING Trademark

GLOBIN SWITCHING is a USPTO trademark filed by Cellarity, Inc.. Status: Pending.

Trademark Facts

MarkGLOBIN SWITCHING
Serial Number99204288
StatusPending
Filing Date2025-05-27
Mark TypeWord
Nice Classes005 (Pharmaceuticals), 042 (Software & IT), 044 (Medical Services)
OwnerCellarity, Inc.
Attorney of RecordChristina M. Licursi
Prosecution Events15
Latest EventCNFR on 2026-05-05

Goods & Services

Class 005: Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders; Class 042: Research and development of new products in the nature of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of medicine and diagnostic testing featuring pharmaceutical, therapeutic and biopharmaceutical preparations and agents; pharmaceutical drug development and research; scientific research in the field of drug discovery and development; biomedical research services; pharmaceutical drug development services, namely, preclinical development of therapeutic products; bioinformatic services in the nature of scientific research, namely, collecting and analyzing complex biological data through the use of artificial intelligence; providing temporary use of non-downloadable artificial intelligence (AI) computer software for molecular design in the fields of pharmaceutical research, medicine, and diagnostic testing for disease; scientific diagnostic and screening services for scientific research purposes, namely, conducting scientific diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics and research relating to drug development; providing on-line non-downloadable artificial intelligence (AI) software for the capture, collection, conversion, analysis, transmission, processing, receiving, recording, storage and transmission of data, images, information in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable artificial intelligence (AI) software featuring machine learning for data analysis in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable artificial intelligence (AI) software featuring machine learning for drug analysis in drug discovery and development; scientific research, namely, research and analysis services in the scientific fields of artificial intelligence and machine learning analytics, healthcare, biomedical and genomic research; providing on-line non-downloadable artificial intelligence (AI) software featuring machine learning for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks in the field of scientific research; medical research services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; Class 044: Medical diagnostic and screening services in the fields of medicine, diagnostic testing, molecular evaluation, and combating of diseases utilizing artificial intelligence and molecular research

Recent Prosecution Activity

DateDocumentType
2026-04-14Response to Office ActionROA
2026-01-06Application Extension to ResponseELR
2025-10-15XSearch Search SummaryXSS
2025-10-15Non-Final ActionNFIN
2025-05-27ApplicationAPP

USPTO Refusals on Record

Related